Epilepsy

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending October 2, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 2, 2020.

The use of statins was also associated with a reduced risk of SUDEP, but there were no reduced risks with SSRIs or other antidepressants, neuroleptics, or beta-blockers.

The primary objective of the trial is to demonstrate that lorcaserin has superior efficacy compared to placebo as measured by percent change in frequency of convulsive seizures per 28 days.

Learn more about the 2020 Dash For Dravet, hosted by the Dravet Syndrome Foundation.

Aquestive Therapeutics plans to provide the agency with information on pharmacokinetic modeling to demonstrate that the desired levels of diazepam exposure can be achieved with dose adjustments.

Sucheta M. Joshi, MD, MS, and Nicholas Beimer, MD, detail the potential benefit the EpiTRAQ tool has from both a patient and clinician perspective.

Martina Bebin, MD, professor of neurology and pediatrics at the University of Alabama at Birmingham Epilepsy Center, detailed the importance of cannabidiol for treatment of TSC.

Neurology News Network for the week ending September 26, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 25, 2020.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with David Vossler, MD.

Notably, no patients received a dose and route consistent with national guidelines.

The professor of neurology and pediatrics at University of Alabama at Birmingham Epilepsy Center discussed the FDA approval of epidiolex for patients with tuberous sclerosis complex.

The positive top-line data from Study 3 revealed that children with Dravet syndrome experienced more than a 60% greater reduction in mean monthly convulsive seizures compared to placebo.

Marinus Pharmaceuticals’ positive allosteric GABAA receptor modulator ganaxolone was associated with significant median reductions in 28-day major motor seizure frequency compared to placebo.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 18, 2020.

In part 2 of this interview, Leah Croll, MD, a neurology resident on the front lines of the COVID-19 pandemic, describes how her resident program experience was impacted by the pandemic.

Day of Dravet, a 1-day virtual event on Saturday, October 17th will give attendees an opportunity to meet industry representatives and ask questions.

Sucheta M. Joshi, MD, MS, and Nicholas Beimer, MD, discuss their experience with EpiTRAQ and the role it can play in optimizing the epilepsy care transition.

The 7th International LGS Foundation Family Conference features interactive Q&A's, breakout sessions, interactive games, and access to the after party with LGS caregivers.

Register now to participate in the Dravet Syndrome Foundation's Virtual Steps Toward a cure beginning September 19th.

Neurology News Network for the week ending September 12, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 11, 2020.

Leah Croll, MD, a neurology resident on the front lines of the COVID-19 pandemic, shares details from her study on the psychosocial impact on physicians and her first-hand experience.